alexa Current novel approaches in systemic therapy of atopic dermatitis: specific inhibition of cutaneous Th2 polarized inflammation and itch.
Immunology

Immunology

Immunogenetics: Open Access

Author(s): Werfel T, Biedermann T, Werfel T, Biedermann T

Abstract Share this page

Abstract PURPOSE OF REVIEW: This present review gives an overview on different approaches on systemic treatment of atopic dermatitis with a focus on molecules that are presently investigated as defined target structures in clinical studies with patients with atopic dermatitis. RECENT FINDINGS: Available systemic drugs for the treatment of atopic dermatitis are limited. There is a high need for the development of new treatment regimen. Current studies address novel biologicals or small molecules for the treatment of atopic dermatitis. In particular, interventions in the T-helper 2 cell (Th2) allergic inflammation are promising. Dupilumab, a humanized monoclonal antibody to the interteukin-4R is the first antibody (i.e. 'biological') with published efficacy shown in controlled prospective studies in atopic dermatitis. A number of other target molecules is currently addressed in clinical studies with blocking antibodies against target molecules of Th2 polarized inflammation in atopic dermatitis (e.g. interleukins 13, 22, 31, thymic stromal lymphopoetin). Inhibiting phospodiesterase-4, chemoattractant receptor-homologous molecule 2, the histamine-4 receptor, or the neurokine-1 receptor may lead to the approval of novel 'small drugs' for a specific treatment of atopic dermatitis. Antifungals may be helpful in the variant of head and neck dermatitis associated with sensitizations against Malassezia species. Induction of specific immune tolerance (e.g. with allergen-specific immunotherapy) should be further studied in terms of the management of atopic dermatitis because available clinical studies resulted in inconsistent results on the skin condition. SUMMARY: Current studies with new substances for the systemic treatment of atopic dermatitis have tremendous implications for the future management of atopic dermatitis. This article was published in Curr Opin Allergy Clin Immunol and referenced in Immunogenetics: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords